Sharpe ratio is not yet available for VRNA. This metric requires at least 12 months of historical daily returns to calculate. Check back once this data is available.
How it compares to other similar stocks
The table compares Verona Pharma plc's Sharpe Ratio with other stocks in the Biotechnology industry across multiple time periods, showing how VRNA's risk-adjusted performance compares to industry peers.
Data shows 1-, 5-, and 10-year periods, plus each stock's all-time average, as of Jun 25, 2026.
| Symbol | Name | 1Y Sharpe Ratio | 5Y Sharpe Ratio | 10Y Sharpe Ratio | All Time Sharpe Ratio |
|---|---|---|---|---|---|
| RVMDW | Revolution Medicines Inc. Warrant | 13.99 | |||
| SLGL | Sol-Gel Technologies Ltd. | 9.11 | |||
| CLYM | Climb Bio Inc | 9.08 | |||
| ERAS | Erasca, Inc. | 9.08 | |||
| RLMD | Relmada Therapeutics, Inc. | 8.27 | |||
| ORKA | Oruka Therapeutics, Inc | 7.85 | |||
| ANRO | Alto Neuroscience, Inc | 7.05 | |||
| LQDA | Liquidia Corporation | 6.83 | |||
| KOD | Kodiak Sciences Inc. | 6.66 | |||
| SYRE | Spyre Therapeutics Inc. | 6.65 | |||
| VRNA | Verona Pharma plc | — |
Loading charts...
Sharpe Ratio Calculator
How does VRNA fit in your portfolio?
Add your other holdings to see your portfolio's Sharpe Ratio and find out.
Analyze Your Portfolio